Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies for cancer and eye diseases. The Company focuses on developing activities that covers targets, including vascular endothelial growth factors (VEGF-C, VEGF-D and VEGF receptor-3). It develops therapies for the treatment of diseases associated with blood and lymphatic vessel growth, such as angiogenesis, lymphangiogenesis and vascular leakage.
Reporte del Mercado Australiano, 6 de abril de 2011 incluye: La subsidiaria de Motopia Limited (ASX:MOT), cBox Pty Ltd, designada como distribuidor mediático de Business Wire en Australia; MACA Limited (ASX:MLD), proveedor de servicios de trituración y exploración para WPG Resources Limited (ASX:WPG); Rey Resources Limited (ASX:REY) anuncia incremento de Recursos Medidos en Proyecto de Carbón Térmico Duchess Paradise; Circadian Technologies Limited (ASX:CIR) afirma que VGX-100 inhibe significativamente crecimiento y propagación de varios tipos de tumores cancerígenos.
© 2024 ABN Newswire. All Rights reserved.